Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty Drugsharvard pilgrim health care Step Therapy Prior Aut…
    Ask Trek AI about this page
    Currentharvard pilgrim health carePolicy N/A

    2026 Step Therapy Prior Authorization Medical Necessity Guidelines

    Customize your policy alerts

    Sign up for all harvard pilgrim health care policy alerts

    Know when harvard pilgrim health care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Step therapy prior authorization rules for specified drug products (antidepressants, atypical antipsychotics, inhaled corticosteroids, interferons) for Harvard Pilgrim Health Care members; outlines required prior medication fills or documentation to bypass authorization.

    Policy Summary
    Payerharvard pilgrim health care
    Policy2026 Step Therapy Prior Authorization Medical Necessity Guidelines
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateAug 1, 2026
    Next Review DateN/A
    Key ActionProvide paid pharmacy claims or physician documentation showing required Step-1 (or Step-2 where allowed) fills within the previous 180 days to support coverage of Step-2 drugs.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4therapeutic categories listed
    180look-back period (days)
    2step levels
    multipleproducts indexed

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria by Therapeutic Category

    Antidepressants

    Antidepressants - Covered when conditions below are met

    Antidepressant Step-1 coverage: Member may receive Step-1 listed antidepressants without prior authorization (includes bupropion, bupropion SR, bupropion XL, citalopram, desvenlafaxine ER, duloxetine delayed-release capsules, escitalopram, fluoxetine, fluoxetine delayed-release, fluvoxamine, paroxetine, sertraline, venlafaxine, and venlafaxine ER)

    source: chunk 4

    Antidepressant Step-2 coverage: Emsam, Fetzima (and Fetzima Titration Pack), and Exxua (and Exxua Titration Pack) are Step-2 and are covered only if the member has a paid claim or physician documentation showing a fill for a Step-1 or Step-2 medication within the previous 180 days180 days

    source: chunk 4

    Atypical Antipsychotics

    Atypical antipsychotics - Covered when conditions below are met

    Atypical antipsychotic Step-1 coverage: Aripiprazole, lurasidone, olanzapine, olanzapine-fluoxetine, quetiapine, risperidone, and ziprasidone are Step-1 and covered without authorization

    source: chunk 7

    Atypical antipsychotic Step-2 coverage: Asenapine and Fanapt (and Fanapt Titration Pack A) are Step-2 and are covered if the member has filled one or more Step-1 or Step-2 medications within the previous 180 days as evidenced by a paid claim or physician documentation180 days

    source: chunk 7

    Inhaled Corticosteroids

    Inhaled corticosteroids - Covered when conditions below are met

    Inhaled corticosteroid Step-1 coverage: QVAR is Step-1 and covered without authorization

    source: chunk 10

    Inhaled corticosteroid Step-2 coverage: Fluticasone propionate (Diskus/HFA) are Step-2 and will be covered if the member has filled one or more Step-1 medications within the previous 180 days as evidenced by a paid claim or physician documentation180 days

    source: chunk 10

    Interferons

    Interferons - Covered when conditions below are met

    Interferon Step-1 coverage: Avonex, Betaseron, and Plegridy are Step-1 and covered without prior authorization

    source: chunk 13

    Interferon Step-2 coverage: Rebif and Rebif Rebidose (and Rebif/Rebidose titration packs) are Step-2 and will be covered if the member has filled for two or more Step-1 medications within the previous 180 days as evidenced by a paid claim or physician documentation2 fills within 180 days

    source: chunk 13

    Coding and Look-back Period

    Look-back period — prior fills required for step therapy
    Look-back period180 days
    Evidence requiredPaid pharmacy claim or physician documentation demonstrating the required prior fill(s)
    Applies toStep-2 drugs across antidepressants, atypical antipsychotics, inhaled corticosteroids, and interferons
    Interferon-specific requirementRebif and Rebif Rebidose require evidence of two or more Step-1 fills within the previous 180 days
    Standard prior-fill countOne or more Step-1 (or Step-2 where allowed) fills within 180 days for most Step-2 products

    Provider Actions, Documentation, and Prior Authorization Requirements

    Prior Authorization

    Step-2 prior authorization requirement

    Certain listed Step-2 drugs require prior authorization unless the member has evidence of a qualifying prior fill or physician documentation within the 180-day look-back period. Providers must submit paid pharmacy claims or physician documentation showing the required prior medication trial to avoid prior authorization denial for Step-2 products.

    • Look-back period: 180 days (evidence via paid claim or physician documentation).
    Step Therapy

    Antidepressants step therapy — Step‑1 vs Step‑2

    Step-1 antidepressants (bupropion formulations, citalopram, desvenlafaxine ER, duloxetine delayed‑release capsules, escitalopram, fluoxetine formulations, fluvoxamine, paroxetine, sertraline, venlafaxine and venlafaxine ER) are covered without prior authorization. Emsam, Fetzima (including Fetzima Titration Pack), and Exxua are Step-2 and require evidence of a paid claim or physician documentation showing a fill for a Step-1 or Step-2 antidepressant within the previous 180 days to be covered.

    Step-Therapy Operational Rules and Member Fill Requirements

    RequirementCoverage
    Member must have filled for a Step-1 or Step-2 antidepressant within the previous 180 days (paid claim) or provide physician documentation
    Step-2 antidepressants (Emsam, Fetzima, Exxua, including titration packs) will be covered when the prior fill or documentation requirement is met
    RequirementCoverage
    Member must have filled for one or more Step-1 or Step-2 atypical antipsychotics within the previous 180 days (paid claim) or provide physician documentation
    Step-2 atypical antipsychotics (asenapine, Fanapt, including Fanapt titration pack) will be covered when the prior fill or documentation requirement is met
    RequirementCoverage
    Member must have filled for one or more Step-1 inhaled corticosteroids within the previous 180 days (paid claim) or provide physician documentation
    Step-2 inhaled corticosteroid products (fluticasone formulations) will be covered when the prior fill or documentation requirement is met
    RequirementCoverage
    Member must have filled for two or more Step-1 interferon medications within the previous 180 days (paid claims) or provide physician documentation
    Step-2 interferons (Rebif, Rebif Rebidose, and titration packs) will be covered when the two-fill prior requirement or documentation is met
    Policy Summary
    Payerharvard pilgrim health care
    Policy2026 Step Therapy Prior Authorization Medical Necessity Guidelines
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateAug 1, 2026
    Next Review DateN/A
    Key ActionProvide paid pharmacy claims or physician documentation showing required Step-1 (or Step-2 where allowed) fills within the previous 180 days to support coverage of Step-2 drugs.
    SourceLink
    On This Page
    Coverage Criteria by Therapeutic CategoryCoding and Look-back PeriodProvider Actions, Documentation, and Prior Authorization RequirementsStep-Therapy Operational Rules and Member Fill Requirements
  1. Step-1 (no prior auth): bupropion, bupropion SR, bupropion XL, citalopram, desvenlafaxine ER, duloxetine delayed‑release capsules, escitalopram, fluoxetine, fluoxetine delayed‑release, fluvoxamine, paroxetine, sertraline, venlafaxine, venlafaxine ER.
  2. Step-2 (require prior fill/documentation): Emsam, Fetzima, Exxua (includes Fetzima Titration Pack).
  3. Step Therapy

    Atypical antipsychotics step therapy — Step‑1 vs Step‑2

    Certain atypical antipsychotics listed as Step-1 (aripiprazole, lurasidone, olanzapine, olanzapine‑fluoxetine, quetiapine, risperidone, ziprasidone) are covered without authorization. Asenapine and Fanapt (including Fanapt Titration Pack A) are Step-2 and will be covered only if the member has filled one or more Step-1 or Step-2 atypical antipsychotics within the previous 180 days as evidenced by a paid claim or physician documentation.

    • Step-1 (no prior auth): aripiprazole, lurasidone, olanzapine, olanzapine‑fluoxetine, quetiapine, risperidone, ziprasidone.
    • Step-2 (require prior fill/documentation): asenapine, Fanapt (Fanapt Titration Pack A).
    Step Therapy

    Inhaled corticosteroids step therapy — QVAR (Step‑1) and fluticasone (Step‑2)

    QVAR is designated Step-1 and is covered without prior authorization. Fluticasone products (e.g., Fluticasone Propionate HFA/Diskus) are Step-2 and will be covered only if the member has filled one or more Step-1 inhaled corticosteroids within the previous 180 days as evidenced by a paid claim or physician documentation.

    • Step-1 (no prior auth): QVAR.
    • Step-2 (require prior fill/documentation): fluticasone products (Fluticasone Propionate HFA/Diskus).
    Step Therapy

    Interferons step therapy — Step‑1 vs Step‑2 (two‑fill requirement)

    Avonex, Betaseron, and Plegridy are Step-1 and covered without prior authorization. Rebif and Rebif Rebidose (including their titration packs) are Step-2 and will be covered only if the member has filled two or more Step-1 interferon medications within the previous 180 days as evidenced by paid pharmacy claims or physician documentation.

    • Step-1 (no prior auth): Avonex, Betaseron, Plegridy.
    • Step-2 (require two prior fills/documentation): Rebif, Rebif Rebidose, and their titration packs — requires evidence of two or more Step‑1 fills within 180 days.
    Documentation Required

    Evidence of prior medication trials (documentation required)

    Physician documentation or paid pharmacy claims must show the member filled the required Step-1 (or Step-2 where permitted) medications within the prior 180 days to support coverage of Step-2 products. Absence of this evidence may result in denial of coverage for Step-2 drugs.

    • Acceptable evidence: paid pharmacy claim(s) within 180 days or physician documentation confirming the fill(s).
    • Interferons specifically require two or more Step‑1 fills within 180 days for Step‑2 coverage.
    Denial Risk

    Prior fill requirement for Step‑2 drugs (denial risk)

    Coverage for Step-2 medications requires evidence of the required number of prior fills within the previous 180 days: one or more fills for most Step-2 drugs, but two or more fills for interferon Step-2 products; failure to provide this evidence may lead to denial.

    • Antidepressants, atypical antipsychotics, and inhaled corticosteroids: evidence of one or more Step‑1 (or Step‑2 where allowed) fills within 180 days.
    • Interferons: evidence of two or more Step‑1 fills within 180 days for Step‑2 coverage.